TREND OF MDR-TB IN KIRKUK- IRAQ-A 10 YEARS’ EXPERIENCE AND CHALLENGES
Keywords:
MDR-TB, Kirkuk- IraqAbstract
Tuberculosis is still regarded as one of major public health burden worldwide, and the emergence of multi-drug resistant TB which is defined by resistance to both Isoniazid (INH) and Rifampicin (R) with or without resistance together drug; is adding problems to public health across the continents.(1),(2) The probable causes of increasing the prevalence of multi-drugs resistance (MDR) may be attributed to the emergence of human immunodeficiency virus (HIV), poverty, migration narcotic abuse and displacement following wars, finally the poor performance of National Tuberculosis Program Strategy (NTPS) may be one of the contributing factors, as irregular treatment is worse than no treatment of initial Tuberculosis (TB) cases.(3),(4) Iraq is one of Eastern Mediterranean Region Organization (EMRO) countries and it has intermediate to relatively high burden of TB rate (651100000).(3) Although drug resistance to antibiotics is a natural phenomenon, but in case of TB it is regarded as manmade, which is attributed to interrupted treatment and poor health serves, here, it is crucial to explore types of drug resistance to anti TB, actually two important patterns of drug resistance had rayed attention, they are the multidrug resistant (MDR) and extensively drug resistant (XDR). MDR being resistant to at least INH and Rifampicin, while (XDR) is defined as MDR TB with resistance to at least aflouroquinolone and one-second line injectable agent (amikacin, kanamycin and / or caprcomycin).(5),(6)
References
1-TB India DOTS plus Guidelines 2012, RNTCP
status Report. (2010).
2-Kants, Maurya AK, Kushwaha RA, et al.
Multidrug-resistant tuberculosis. An Iatrogenic
problem. Biosu-Trend, 2010; 4: 48-55.
3-WHO reporet 2009. Global Tuberculosis
Control: epidemiology, Strategy, financing.
WHO/HTM/TB/ 2009. 411 Geneva. 2009.
4-First insight into the drug resistance pattern
of Mycobacterium tuberculosis in Dohuk Iraq:
using spoligtyping and MRUVNTR to
characterize MDR strains. Merza M A, Farnia P,
Salih A, et al. Journal of Infection and Public
Health, 2011: 4; 41-47.
5-Gandhi NR, Nunn P, Dheda K, et al.
Multidrug-resistant and extensively drugresistant tuberculosis: a threat to global
control of tuberculosis. lancet 375, (2010):
-1843.
6-Johnston JC, Shahidi NC, Sadatsafavi M, et
al. Treatment outcomes of multi-drug resistant
tuberculosis: a systematic review and metaanalysis, PLOS One 4. (2009) e 614.
7-Schaberg T, Reichert B, Schulin T, et al.
Rapid drug Susceptibility testing
Mycobacterium tuberculosis using conventional
solid media. EurRespir. J. (1995); 8: 1688-93.
8-WHO. Global Tuberculosis Report. Geneva.
(2016).
9-WHO. Eleventh meeting of the regional
Green Light committee for the Eastern
Mediterranean, (2019).
10-Wold Health Organization. Global Health
estimates 2016. Death by cause, age, sex, by
country and by region, 2000-2016. Geruva,
WHO.2018.
11-WHO. Guidelines for surveillance of drug
resistance Tuberculosis. 4th. Ed. Geneva. 2021.
12-WHO. Global Tuberculosis Report. 2012
13-Maurya AK, Singh AK, Kumar M, et al.
Changing patterns and trends of multidrugresistant tuberculosis at refer Center in
Northern India: A 4- year experience IndianJournal of Medical microbiology; 2013, 31 41-
14-Dunachie S, Chamnan P, The double
burden of diabetes and global infection in low
and middle- income countries. Trans R Soc
Trop Med Hyg. 2019; 113: 56- 64.
15-Shenoi S, Friedland G. Extensively drug
resistant tuberculosis: a new face to an old
pathogen. Annu Rev Med. 2009; 60: 307- 20.
16-Seddon JA, Hesseling CA, Willemse M, et
al. Culture. Confirmed MDR tuberculosis in
children clinical feature, treatment, and
outcome. Clininfe Dis J. 2012; 54 (2): 157- 66.
17-Jenkns HE, Year MC. The burden of multidrug resistant tuberculosis in children. Int J
Tuber lung Dise. 2018; 22 (5): 3- 6.
18-Al- Obaidy MW. A prevalence of drugresistance previously treated Tuberculosis
patient in Baghdad. The Iraqi postgraduate.
Medical Journal. 2013; 12: 626- 631.
19-Mohammed Kh A, KhudharCh S, Al- Rabeai
DB. Prevalence and drug resistance pattern of
Mycobacterium tuberculosis isolated from
Tuberculosis patients in Basrah, Iraq. Polish
Journal of Microbiology. 2022; 71 (2): 205-
20-Kapata N, KapataPch, Bates M, et al.
Multidrug- resistant tb in Zambia: Review of
national data from 2000- 2011. Tropical
medicine and International Health. 2011
(11); 1386-1391.
21-Faye LM, Hosu MC, Iruedo J, et al.
Treatment outcomes and Associated factors
among tuberculosis patients from selected
Rural Eastern Cape Hospital. An Am
bidirectional study Tropical medicine and
Infectious disease 2023; 8: 315.
22-WHO. Summary report on the Eleventh
meeting of the regional Green Light
Committee for the Eastern Mediterranean.
Pakistan. Pp- 5.
23-Health Department: Republic of South
Africa. Management of Rifampicin Resistant
Tuberculosis. A clinical Reference Guide. 2019.
TB booklet 0220 VII, indd3.
24-Akalu TY, Clement AC, Wolde H and Alene
KA. Economic burden of multi; drug- resistant
tuberculosis on patients and households: A
global systematic revieal and meta- analysis
Scientific Report Nature Port Polio, 2023; 13:
Lecai J, Mijiti P, Chuangyue H, et al.
Treatment outcome of multi- resistant
tuberculosis patients receiving ambulatory
treatment in Shenzhen, China: a retrospective
cohort study. Frontiers in Public Health. 2023.
DOI. 10. 3389/ f pubh. 2023. 1134934.
Oladimeji O, Atiba BP, Anyiam FE, et al.
Gender and Drug-resistant tuberculosis in
Nigeria. Tropical Medicine and Infectious
Diseases. 2023: 8; 104
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.